A. I. Staroverova
Research Subjects
A. I. Staroverova has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Ekaterina S. Kropacheva
Chazov National Medical Research Center of Cardiology
5 shared publications - Elizaveta P. Panchenko
Research Centre for Medical Genetics, Moskvorechye st., 1, Moscow 115522, Russia
5 shared publications - Alexey E. Komlev
Chazov National Medical Research Centre of Cardiology
2 shared publications - Anatoly B. Dobrovolsky
Chazov National Medical Research Center of Cardiology
2 shared publications - Elena V. Titaeva
Chazov National Medical Research Center of Cardiology
2 shared publications - Timur E. Imaev
Institute of Clinical Cardiology named after A. L. Myasnikov of the National Medical Research Center for Cardiology named after academician E. I. Chazov of the Ministry of Health of the Russian Federation
2 shared publications
Latest Publications
- Open Access
- 2 August 2023
- Published by Remedium, Ltd. in Atherothrombosis
- Vol. 13 (1) , 46-57
Need to determine the residual concentrations of direct oral anticoagulants in patients with atrial fibrillation undergoing transcatheter implantation of the aortic valve
Introduction. Lengthening the period of direct oral anticoagulant (DOAC) withdrawal before intervention is not allowed. Chronic kidney disease (CKD), impaired liver function, extremely low or high body mass, chronic heart failure (CHF), and age > 90 years can increase blood DOAC levels. DOAC therapy does not require routine laboratory monitoring. However, there are coagulation tests that can be used to detect the presence of a drug in blood. Duration of DOAC discontinuation and the appropriateness of assessing residual anticoagulant concentrations before intervention with a high bleeding risk in a special category of patients is to be defined.Aim. To measure residual concentrations of anticoagulants and their association with perioperative bleeding risk in patients with AF using DOACs in blood samples collected immediately before TAVI.Materials and methods. The 94 patients with atrial fibrillation (AF) included in the study were characterized by senile age, a high risk of thromboembolic complication (ТС), many comorbidities, and a high prevalence of senile asthenia. The apixaban and rivaroxaban concentrations were measured according to the value of anti-Xa activity and control plasmas with normal levels of coagulation factors (Diagnostica Stago, France).Results. The median time of DOAC withdrawal before TAVI was 60 hours [47.5; 72]. However, the DOAC concentration exceeded 30 ng/ml in 1/5 patients (19.2%), and stage 3 or more CKD was more common in these patients. Our study showed the relationship between DOAC concentration and the duration of DOAC withdrawal period. However, the relationship between DOAC concentration and bleeding that occurred in the perioperative period could not be found. Patients with signs of CKD were older and had a lower BMI as compared to patients without CKD.Conclusion. Our data showed the relationship between the DOAC concentration and the duration of DOAC withdrawal period. No relationship was found between DOAC concentrations and bleeding.
- 2 August 2023
- Published by Remedium, Ltd. in Atherothrombosis
- Vol. 13 (1) , 46-57
Open AccessNeed to determine the residual concentrations of direct oral anticoagulants in patients with atrial fibrillation undergoing transcatheter implantation of the aortic valve
Introduction. Lengthening the period of direct oral anticoagulant (DOAC) withdrawal before intervention is not allowed. Chronic kidney disease (CKD), impaired liver function, extremely low or high body mass, chronic heart failure (CHF), and age > 90 years can increase blood DOAC levels. DOAC therapy does not require routine laboratory monitoring. However, there are coagulation tests that can be used to detect the presence of a drug in blood. Duration of DOAC discontinuation and the appropriateness of assessing residual anticoagulant concentrations before intervention with a high bleeding risk in a special category of patients is to be defined.Aim. To measure residual concentrations of anticoagulants and their association with perioperative bleeding risk in patients with AF using DOACs in blood samples collected immediately before TAVI.Materials and methods. The 94 patients with atrial fibrillation (AF) included in the study were characterized by senile age, a high risk of thromboembolic complication (ТС), many comorbidities, and a high prevalence of senile asthenia. The apixaban and rivaroxaban concentrations were measured according to the value of anti-Xa activity and control plasmas with normal levels of coagulation factors (Diagnostica Stago, France).Results. The median time of DOAC withdrawal before TAVI was 60 hours [47.5; 72]. However, the DOAC concentration exceeded 30 ng/ml in 1/5 patients (19.2%), and stage 3 or more CKD was more common in these patients. Our study showed the relationship between DOAC concentration and the duration of DOAC withdrawal period. However, the relationship between DOAC concentration and bleeding that occurred in the perioperative period could not be found. Patients with signs of CKD were older and had a lower BMI as compared to patients without CKD.Conclusion. Our data showed the relationship between the DOAC concentration and the duration of DOAC withdrawal period. No relationship was found between DOAC concentrations and bleeding.
- Open Access
- 28 June 2022
- Published by Remedium, Ltd. in Atherothrombosis
- Vol. 12 (1) , 20-28
Modern possibilities and prospects in evaluating the anticoagulant effect of direct oral anticoagulants
Currently, direct oral anticoagulants (DOACs) should be preferred when prescribing anticoagulant therapy to atrial fibrillation patients because of their lower potential for interactions and risk of bleeding than warfarin. However, in the absence of standardized laboratory tests and a specific antidote (except dabigatran), prescribing and monitoring DOAC therapy remains a challenge for clinicians and patients. The present review focuses on the problems of DOAC laboratory evaluation, indications, and prospects for its use. Routine coagulation tests including activated partial thromboplastin time, prothrombin time and thrombin time are not recommended for DOAC therapy. Currently, there are specific coagulation tests (anti-Xa activity factor determination for apixaban/ rivaroxaban and diluted thrombin time for dabigatran) that allow judging the presence of the drug in the blood. According to current recommendations, these tests should be used only to assess anticoagulant concentrations and not to adjust doses and decide on the timing of withdrawal before invasive intervention. Nevertheless, the issue of determining DOAC concentration during invasive interventions, the need for which only increases with age, is most relevant. Also a possible additional factor that may alter the bioavailability and pharmacokinetics of DOAC and be taken into account in the evaluation of laboratory activity is the presence of chronic renal disease, hepatic insufficiency, low or excess body weight. The use of specific coagulation tests for patients undergoing elective and urgent surgery among special categories of patients (with chronic kidney disease, low or excess body weight, renal failure) is promising.
- 28 June 2022
- Published by Remedium, Ltd. in Atherothrombosis
- Vol. 12 (1) , 20-28
Open AccessModern possibilities and prospects in evaluating the anticoagulant effect of direct oral anticoagulants
Currently, direct oral anticoagulants (DOACs) should be preferred when prescribing anticoagulant therapy to atrial fibrillation patients because of their lower potential for interactions and risk of bleeding than warfarin. However, in the absence of standardized laboratory tests and a specific antidote (except dabigatran), prescribing and monitoring DOAC therapy remains a challenge for clinicians and patients. The present review focuses on the problems of DOAC laboratory evaluation, indications, and prospects for its use. Routine coagulation tests including activated partial thromboplastin time, prothrombin time and thrombin time are not recommended for DOAC therapy. Currently, there are specific coagulation tests (anti-Xa activity factor determination for apixaban/ rivaroxaban and diluted thrombin time for dabigatran) that allow judging the presence of the drug in the blood. According to current recommendations, these tests should be used only to assess anticoagulant concentrations and not to adjust doses and decide on the timing of withdrawal before invasive intervention. Nevertheless, the issue of determining DOAC concentration during invasive interventions, the need for which only increases with age, is most relevant. Also a possible additional factor that may alter the bioavailability and pharmacokinetics of DOAC and be taken into account in the evaluation of laboratory activity is the presence of chronic renal disease, hepatic insufficiency, low or excess body weight. The use of specific coagulation tests for patients undergoing elective and urgent surgery among special categories of patients (with chronic kidney disease, low or excess body weight, renal failure) is promising.
- 1 January 2022
- Published by Media Sphere Publishing Group in Russian Cardiology Bulletin
- Vol. 17 (4)
Unfavorable prognostic factors in patients with atrial fibrillation after successful transcatheter aortic valve implantation
ЦЕЛЬ ИССЛЕДОВАНИЯ Оценить частоту смерти от всех причин и выявить клинические предикторы неблагоприятного прогноза на основании проспективного наблюдения за больными фибрилляцией предсердий (ФП), подвергнутыми транскатетерной имплантации аортального клапана (ТИАК). МАТЕРИАЛ И МЕТОДЫ Исследование представляет собой анализ когорты больных ФП, подвергнутых операции ТИАК в НМИЦ кардиологии им. акад. Е.И. Чазова за 2020—2022 гг. В работу включены 130 пациентов с ФП (61 мужчина), медиана возраста 79 лет. Подавляющее большинство больных относилось к категории высокого риска тромбоэмболических осложнений, медиана суммы баллов по шкале CHA2DS2—VASc составила 5. РЕЗУЛЬТАТЫ Летальность в течение 1,5 года среди больных ФП, перенесших успешную ТИАК, составила 8,4/100 пациенто-лет. В структуре летальности преобладала (73,3%) смерть от сердечно-сосудистых причин. Предикторами ее развития от всех причин среди исследуемой группы пациентов оказались 2 признака: наличие старческой астении и хронической болезни почек ≥III стадии. У больных ФП, переживших операцию ТИАК, предиктором развития всех нежелательных событий в течение 1,5 года наблюдения оказалась онкологическая патология.
- 1 January 2022
- Published by Media Sphere Publishing Group in Russian Cardiology Bulletin
- Vol. 17 (4)
Unfavorable prognostic factors in patients with atrial fibrillation after successful transcatheter aortic valve implantation
ЦЕЛЬ ИССЛЕДОВАНИЯ Оценить частоту смерти от всех причин и выявить клинические предикторы неблагоприятного прогноза на основании проспективного наблюдения за больными фибрилляцией предсердий (ФП), подвергнутыми транскатетерной имплантации аортального клапана (ТИАК). МАТЕРИАЛ И МЕТОДЫ Исследование представляет собой анализ когорты больных ФП, подвергнутых операции ТИАК в НМИЦ кардиологии им. акад. Е.И. Чазова за 2020—2022 гг. В работу включены 130 пациентов с ФП (61 мужчина), медиана возраста 79 лет. Подавляющее большинство больных относилось к категории высокого риска тромбоэмболических осложнений, медиана суммы баллов по шкале CHA2DS2—VASc составила 5. РЕЗУЛЬТАТЫ Летальность в течение 1,5 года среди больных ФП, перенесших успешную ТИАК, составила 8,4/100 пациенто-лет. В структуре летальности преобладала (73,3%) смерть от сердечно-сосудистых причин. Предикторами ее развития от всех причин среди исследуемой группы пациентов оказались 2 признака: наличие старческой астении и хронической болезни почек ≥III стадии. У больных ФП, переживших операцию ТИАК, предиктором развития всех нежелательных событий в течение 1,5 года наблюдения оказалась онкологическая патология.
- Open Access
- 14 October 2020
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 92 (9) , 15-23
Resumption of anticoagulant therapy after major bleeding and recurrence of hemorrhagic complications in patients with atrial fibrillation with a high risk of stroke and thromboembolism (based on the results of 20 years of observation)
Aim.To analyze the frequency of resumption of anticoagulant therapy (ACT) after major and clinically significant bleeding among AF patients who received oral anticoagulants and were observed in the Department of clinical problems of atherothrombosis from 1999 to 2019 within the retro-prospective register Regata-2, and to search for clinical factors associated with recurrence of hemorrhagic complications among patients who resumed anticoagulant therapy after a bleeding episode. Materials and methods.In cohort study of patients with high-risk AF with absolute indications for ACT we enrolled 290 AF patients (130 women and 160 men) aged 32 to 85 years (the average age was 65.188.89 years). During the follow-up period, 92 patients developed hemorrhagic complications, and 73 of them resumed ACT. 35 of the 73 patients who resumed ACT developed a relapse of major/clinically significant bleeding. Results.The frequency of resuming ACT after the first hemorrhagic complication increased over time from 75% in the period from 19992003 to 90% in the period 20152019. We were not able to establish an exact relationship between the presence of concomitant pathology and the decision to resume the ACT after bleeding. The only reliable reason for refusing to resume the ACT was the patients categorical reluctance. Among patients who had recurrent hemorrhagic complications, the total score on the Charleson comorbidity scale was significantly higher (4.232.01vs3.521.43;p=0.0425). Patients with recurrent bleeding were significantly more likely to suffer from CKD with a decrease in GFR less than 60 ml/min/1.73 sq. m, and also had a history of erosive and ulcerative lesions of the gastrointestinal tract. There was also a significant Association of recurrent bleeding with the use of proton pump inhibitors. Subgroups of patients who switched from warfarin to taking direct oral anticoagulants after the first bleeding and subsequent recurrent bleeding did not differ in basic clinical characteristics from patients without bleeding after changing the anticoagulant. According to multiple regression analysis, NSAIDs showed a tendency to develop a relapse of B/C bleeding on the background of direct oral anticoagulants in patients who underwent GO on the background of warfarin therapy (b=0.4524,p=0.0530). Conclusion.During the 20-year follow-up, the frequency of all major and clinically significant bleeding was 2.6/100 patients-years, the frequency of first bleeding was 5.86/100 patients-years, while the frequency of repeated hemorrhagic complications was 7.06/100 patients-years. Patients with a high thromboembolic risk should receive anticoagulants, provided that the modifiable risk factors for bleeding are carefully corrected.
- 14 October 2020
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 92 (9) , 15-23
Open AccessResumption of anticoagulant therapy after major bleeding and recurrence of hemorrhagic complications in patients with atrial fibrillation with a high risk of stroke and thromboembolism (based on the results of 20 years of observation)
Aim.To analyze the frequency of resumption of anticoagulant therapy (ACT) after major and clinically significant bleeding among AF patients who received oral anticoagulants and were observed in the Department of clinical problems of atherothrombosis from 1999 to 2019 within the retro-prospective register Regata-2, and to search for clinical factors associated with recurrence of hemorrhagic complications among patients who resumed anticoagulant therapy after a bleeding episode. Materials and methods.In cohort study of patients with high-risk AF with absolute indications for ACT we enrolled 290 AF patients (130 women and 160 men) aged 32 to 85 years (the average age was 65.188.89 years). During the follow-up period, 92 patients developed hemorrhagic complications, and 73 of them resumed ACT. 35 of the 73 patients who resumed ACT developed a relapse of major/clinically significant bleeding. Results.The frequency of resuming ACT after the first hemorrhagic complication increased over time from 75% in the period from 19992003 to 90% in the period 20152019. We were not able to establish an exact relationship between the presence of concomitant pathology and the decision to resume the ACT after bleeding. The only reliable reason for refusing to resume the ACT was the patients categorical reluctance. Among patients who had recurrent hemorrhagic complications, the total score on the Charleson comorbidity scale was significantly higher (4.232.01vs3.521.43;p=0.0425). Patients with recurrent bleeding were significantly more likely to suffer from CKD with a decrease in GFR less than 60 ml/min/1.73 sq. m, and also had a history of erosive and ulcerative lesions of the gastrointestinal tract. There was also a significant Association of recurrent bleeding with the use of proton pump inhibitors. Subgroups of patients who switched from warfarin to taking direct oral anticoagulants after the first bleeding and subsequent recurrent bleeding did not differ in basic clinical characteristics from patients without bleeding after changing the anticoagulant. According to multiple regression analysis, NSAIDs showed a tendency to develop a relapse of B/C bleeding on the background of direct oral anticoagulants in patients who underwent GO on the background of warfarin therapy (b=0.4524,p=0.0530). Conclusion.During the 20-year follow-up, the frequency of all major and clinically significant bleeding was 2.6/100 patients-years, the frequency of first bleeding was 5.86/100 patients-years, while the frequency of repeated hemorrhagic complications was 7.06/100 patients-years. Patients with a high thromboembolic risk should receive anticoagulants, provided that the modifiable risk factors for bleeding are carefully corrected.